Posted by AGORACOM-JC
at 7:58 PM on Sunday, January 31st, 2021
Beyond Meat has become an $11 BILLION company by creating products designed to emulate beef. The basis of success has come from delivering the experience meat eaters have come to love (hamburgers, hot dogs, etc.) while also achieving the goal of eating healthier.
TAAT™ Beyond Tobacco™ mimics the experiences of cigarettes without nicotine or tobacco. It is engineered to closely emulate the sensory components of smoking a tobacco cigarette, including tasting and smelling just like tobacco.
E-cigarettes and vaping have failed despite existing for 15 years, driving most smokers back to cigarettes because they only perpetuate the problem of nicotine addiction while delivering a completely different user experience to smokers.
Under the leadership of experienced veterans from the tobacco industry, including and especially Philip Morris International, TAAT™ launched in the United States Just 7 weeks ago and has already received repeat orders from more than 60% of convenience and gas station customers.
How good was this launch?
“Out of all of the tobacco category products I have worked with, TAAT™ is an outlier in terms of the level of demand it has had in its early stages. I have launched dozens of new tobacco brands across Canada as well as in the Caribbean, and while many of the new products were reordered by retailers in their first several weeks on the market, none of them were reordered by anywhere near 60% of stores that initially carried them. …. I have confidence that we could replicate these outcomes both in Ohio and in other markets where we may introduce TAAT™ in the future.” – TAAT Chief Revenue Officer Tim Corkum (former commercialization executive for Philip Morris International)
How big is the market TAAT is going after? Tobacco is used by:
34M adults in America, equating to 215 BILLION cigarettes sold in 2018
1.3 billion people worldwide
… and almost all of them aspire to leave nicotine behind. Beyond Tobacco™ from TAAT is about to give them what they want and, if they succeed, give shareholders “Beyond Belief” returns in the next 2-3 years.
Watch this great interview with CEO Setti Coscarella!
Posted by AGORACOM-JC
at 7:42 PM on Sunday, January 31st, 2021
Hollister Biosciences (HOLL:CSE) is a multi-state operator with multiple, high-quality products that are now carried in over 280 dispensaries throughout California and over 90 dispensaries throughout Arizona.
Q4 Highlights:
Record quarterly revenue of CDN$14.93 million and CDN$2.53 million in EBITDA
Venom Extracts is their 100% owned subsidiary that is absolutely dominating the state of Arizona. More than just lip service:
Since the closing (Venom), in the three quarters following, Venom contributed approximately CDN$38 million to the company’s 2020 revenue.
In the entire year of 2020,
Venom generated greater than CDN$ 40 million in revenue (and CDN$ 4.9 million in adjusted EBITDA),
Up from CDN$ 16.4 million in 2019 a 144% year over year revenue increase, and ending the year with a record month of sales for December totaling approximately CDN$5.5 million .
Sold over 4 million grams of product in 2020
accounting for up to 30 percent of category sales statewide in Arizona .
Positioned for continued growth in Arizona with the recently passed adult-use legislation
Marijuana Business Daily projects that Arizona’s recreational market could generate up to $400 million in revenue its first year and more than $700 million by 2024.
….. And it is run by the absolute coolest guy in small cap Cannabis – Jake Cohen
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit www.novamind.ca
Posted by AGORACOM
at 5:16 PM on Friday, January 29th, 2021
Sheldon Kales, Rahul Kushwah, Tomas Sipos and Ajit Kumar re-elected as directors of the company.
TORONTO, ON / ACCESSWIRE / January 29, 2021 / Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the”Company“) is pleased to announce the results of its Annual General and Special Meeting of Shareholders held on January 28, 2021 at 10:00 a.m. (the “Meeting“). The requisite approval of shareholders for the following items, all as more particularly described in the information circular of the Company dated December 21, 2020 (the “Circular“), was received at the Meeting:
1. setting the number of directors of the Company at four;
2. the re-election of Sheldon Kales, Rahul Kushwah, Tomas Sipos and Ajit Kumar as directors of the Company for the ensuing year;
3. the re-appointment of Harbourside CPA LLP (previously Buckley Dodds LLP) as the Company’s auditors; and
4. the authorization of the Company to make an application to the Supreme Court of British Columbia pursuant to Section 229 of Business Corporations Act (British Columbia) (“Section 229 Application“).
The only omissions, defects, errors or irregularities the Company sought to rectify through the Section 229 Application was the Company’s failure to hold an annual general meeting during the 2019 calendar year and distribute interim and annual financial statements. There were no other undisclosed omissions, defects, errors or irregularities that Predictmedix needed to cure.
Posted by AGORACOM
at 9:13 AM on Friday, January 29th, 2021
Tartisan Nickel Corp. (CSE:TN)(OTC PINK:TTSRF)(FSE:A2D) (“Tartisan”, or the “Company”) announces that the Company will conduct a webinar at 12 noon EST on Thursday, February 11th, 2021.
The Company invites investors to join President & CEO Mark Appleby for an update on Tartisan Nickel Corp. and plans for the Company’s flagship Kenbridge Nickel project.
LIVE WEBINAR
The Tartisan Nickel Corp. webinar will take place on Thursday, February 11th, 2021 at 12 noon local time, Toronto.
The following link provides online registration details to join the webinar:
After registering, you will receive a confirmation email containing information about joining the webinar.
The event is being facilitated by PBA (Paul Benwell & Associates).
About Tartisan Nickel Corp.
Tartisan Nickel Corp. is a Canadian based mineral exploration and development company which owns; the Kenbridge Nickel Project in northwestern Ontario; the Sill Lake Silver Property in Sault Ste. Marie, Ontario as well as the Don Pancho Manganese-Zinc-Lead-Silver Project in Peru.
The Company has an equity stake in; Eloro Resources Limited, Class 1 Nickel and Technologies Limited and Peruvian Metals Corp.Tartisan Nickel Corp.
For further information, please contact Mark Appleby, President & CEO and a Director of the Company, at 416-804-0280 ([email protected]).UnfollowRecommend
Posted by AGORACOM
at 1:15 PM on Thursday, January 28th, 2021
Tartisan owns approximately 4 million shares of Eloro Resources
Eloro could amount to between 500 million tonnes to 1 billion tonnes at four to eight ounces silver eq grade
Discovery Hole of 129.6 grams silver equivalent over 257.5 meters
“Eloro is going to be bought out in short order” Bob Moriarty
Potosi in Bolivia is sometimes referred to as the GOAT of silver mining. That is, the Greatest Of All Time for silver. Discovered in 1545, Cerro Rico produced just over 2 billion ounces of silver at a cost of 8 million lives of slaves. If you held two and a half 100 ounce silver bars that came from Potosi, that would have cost the life of one slave, either Indian or Negro. The silver from Potosi funded the Spanish Empire for two and a half centuries. The silver went to Manila before being traded to China for tea, Chinaware and silk. The opium wars weren’t really about opium; they were about the silver riches from Potosi. Spain mined it and traded to China. China had it. Britain wanted it.
It appears Eloro is on track to pushing Potosi aside as the silver GOAT. At least if you are willing to consider silver equivalent ounces. Quinton Hennigh has done several interviews and believes Eloro could amount to between 500 million tonnes to 1 billion tonnes at four to eight ounces silver eq grade. Well, yesterday Eloro came out with brilliant assays that support Quinton’s belief and actually suggests he may have underestimated the potential. Now it seems to imply over 1 billion tonnes. If the four ounces held, Eloro would be the biggest silver story in history. Certainly the biggest silver story in the last fifty years.
Eloro has one of the strongest mining and geology teams in Peru or Bolivia. Dr. Osvaldo Acre runs the Bolivian operation. He is the world’s leading expert on Potosi type systems and literally has written the book about them. Dr. Bill Pearson who I first met when he was leading the geological team at Desert Sun fifteen years ago is the senior technical advisor. Tom Larsen is the CEO and drives the company. Quinton Hennigh also serves as a technical and business advisor.
Eloro has an option on 99% of the Iska Iska property in the very southern bit of Bolivia near Potosi. They are paying the owner 500,000 shares and $10 million USD at some point in the next four years. There is no NSR. The owner retains a 1% interest in the project.
If you look at the center of the concession outlined in blue, clearly there is a caldera. While the geological team has been focused on identifying and drilling breccia pipes with great success, they have also identified a series of more potential pipes to the east and south.
I have never seen any company move a project forward and prove their theory so quickly. In the results released on January 26th one hole measured 129.6 grams silver equivalent over 257.5 meters from the newly discovered Santa Barbara breccia pipe. The Santa Barbara pipe was discovered and announced in the November press release. Through surface mapping and Aster satellite data located yet another breccia pipe, this one named the Central Breccia Pipe measuring 700 meters by 400 meters. This latest set of assays discusses drilling into both the Santa Barbara pipe and the Central Breccis pipe. Those results have not been released yet. Those include hole DHK-02 intercepting 475 meters below surface in the Central Breccia pipe.
This is an interesting system because it has a variety of minerals of economic value including almost an ounce of silver, some gold, lead, zinc, tin, bismuth, indium and cadmium. Quinton Hennigh did up a spreadsheet with the values from the 257-meter hole and it showed a total in the ground value of $103 US per tonne. That would make 500 million tonnes worth somewhere in the $50 billion USD range.
Eloro is going to be bought out in short order, I’m talking 6-12 months. They are fully financed for a planned 14,000 meters of drilling both from surface and from underground. Due to drill limits, the underground drilling is pretty much limited to 350 meters but they can drill 1.2 km holes from the surface.
Today’s price action gives the company about a $190 million CAD market cap. The price is going to be up and down like a bride’s nightie but in six months it’s going to be a hell of a lot higher.
The shares were as cheap as $2.10 a week ago and hit $4.11 on Wednesday the 27th for almost double in a week. While they were cheap a week ago, they got expensive in a hurry. There is a backdoor way to buy shares that have not yet exploded higher yet. Cartier Iron, a gold company run by Tom Larsen, CEO of ELO, happens to own 2.09 million shares of ELO. At today’s highest price for Eloro, the shares held by Cartier were worth more than their entire market cap. The shares were 25% higher ten days ago. That situation won’t last for long.
Eloro and Cartier are both advertisers. I have bought shares in the open market and participated in private placements for both companies. As always do your own due diligence.
Posted by AGORACOM
at 10:48 AM on Thursday, January 28th, 2021
Red Light Holland Corp. (CSE: TRIP) (“Red Light Holland” or the “Company“), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is pleased to announce that it has closed its previously announced bought deal short form prospectus offering, including the exercise in full of the underwriter’s over-allotment option (the “Offering“). In connection with the Offering, the Company issued 38,334,100 units of the Company (the “Units“) at a price of $0.255 per Unit, for aggregate gross proceeds of $9,775,195. The Offering was conducted by Eight Capital (the “Underwriter“).
“To have Red Light Holland – The People’s Company, being supported by ‘The Suits’ alongside our new and existing shareholders truly strengthens our Psychedelic Movement and our growth. We are so grateful for all of our loyal supporters and we now have over $20 million[1] of capital available which is incredible! This funding will enable us to fully execute on our business plan and the Red Light Holland team will continue working hard towards our goal of developing a leading brand in this emerging industry. Our mission continues – providing legal and responsible adult access now,” said Todd Shapiro, CEO and Director of Red Light Holland.
Posted by AGORACOM-JC
at 10:32 AM on Thursday, January 28th, 2021
Tim Daniels / Executive Chairman of AI/ML Innovations Inc. / (CSE:AIML / OTC:FIRZF) explains how the Toronto-based business is focusing on acquiring and furthering Artificial Intelligence and Machine Learning technologies that can address urgent societal needs.
The firm’s key subsidiary, Health Gauge, is a leading digital health solutions provider that’s poised to disrupt the traditional healthcare industry by providing A.I. innovations and services that improve health outcomes, while at the same time reducing costs and stresses on the overburdened healthcare infrastructure.
AI/ML Highlights:
Recently showcased its proof-of-concept deployment in a study funded by The Bill and Melinda Gates Foundation
Health Gauge aims to penetrate the $245bn global digital health monitoring market by partnering with leading channel partners, health benefits providers, and end-users
Will do this via its proprietary combination of digital health monitoring devices, AI-based software, and cloud computing platform.
Take a seat and learn more about AI/ML and its ambitious vision for the future.
Posted by AGORACOM-JC
at 9:30 AM on Thursday, January 28th, 2021
Phil Waddington / President and CEO of Molecule Holdings Inc. / (MLCL:CSE) discusses the craft-focused, cannabis beverage production company’s cutting-edge work in the nascent Canadian market.
Boasting a 200,000 square foot production facility based in Ontario, the company has just been given the green light to begin selling its unique line of cannabis-infused beverages throughout Canada, starting in Ontario and Québec.
The company’s recent partnership with Vortex Cannabis Inc. allows Molecule to bring its unique line of cannabis-infused beverage products to market this year, while completing its own sales amendment application.
Molecule Highlights:
Molecule’s recent deal with Vortex Cannabis Inc. allows it to begin selling its unique line of cannabis-infused beverages throughout Canada this year.
Vortex will sell products produced by Molecule to provincial retailers, starting with Ontario and Québec.
Molecule has a 200,000 square foot production facility based in Ontario, offering huge capacity.
The company forecasts 2021 Q1 revenue of $3.5m, 2021 Q2 revenue of $5.8m, and a 2021 Run Rate revenue of $18.5m
An early leap of faith into this emerging industry in 2018 has positioned the company well ahead of the pack now.
“We are excited to move into full scale production and sale,” says CEO Phil Waddington.
Posted by AGORACOM
at 7:56 AM on Thursday, January 28th, 2021
Construction of commercial drug manufacturing facility in Germany
Four clinical studies in neurological indications in 2021
Development of oral biosensor and contract development & manufacturing
Psychedelic transdermal and sublingual drug formulation development
VANCOUVER, BC / ACCESSWIRE / January 28, 2021 /XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) (“XPhyto” or the “Company“) is pleased to announce its drug formulation and delivery business strategy and milestones for 2021. As a bioscience accelerator at the leading-edge of the life science industry, XPhyto targets growth through commercialization of its product pipeline and focused investment in impact driven innovation with the potential for meaningful value creation.
Further to XPhyto’s press release dated January 18, 2021, the Company’s core milestones for this year include the commercialization of infectious disease diagnostics, the clinical validation of transdermal and sublingual drug formulations and continued investment in psychedelic medicine.
Regarding XPhyto’s drug formulation business, the Company is pleased to set out the strategy and milestones for 2021 of its wholly owned German subsidiary, Vektor Pharma TF GmbH (“Vektor”). Vektor will position itself for commercial manufacturing, pipeline development and drug formulations for critical mental health conditions.
“2021 is expected to be a transformative year for Vektor. We will be building on significant momentum from 2020 as we advance our drug formulation, contract development, and psychedelic business,” said Prof. Dr. Thomas Beckert, managing director of Vektor Pharma TF GmbH. “The addition of scalable in-house manufacturing capability creates the potential for significant growth across virtually all of our development and commercialization programs.”
Vektor is a German narcotics manufacturer, developer, and researcher located in the district of Biberach, Baden-Württemberg, Germany. For over a decade, the company and its team have been leaders in the design, testing and manufacture of thin film drug formulations, particularly transdermal patches and sub-lingual (oral) strips for the delivery of active pharmaceutical ingredients (“API”) for the treatment of pain and neurological conditions.
